Treatments of hepatitis C virus have been developed and increased the sustained virology response (SVR),
however, there are several reports of drug resistance, high-cost issue, and limited access to current hepatitis C virus
(HCV) treatment that remain become a problem. This necessitates to search for complementary and alternative drugs
against HCV, therefore the investigation of active compounds from plant extracts such as Melicope latifolia, a plant that
has been reported as anti-HCV, will be provided in this study. The anti-HCV activities were tested using in vitro
cultured cells of hepatocyte cell line Huh 7.5 and HCV genotype 2a (J6/JFH1). Ethanol extract of M. latifolia leaves was
separated by chromatographic methods and the chemical structures of the isolated compounds were established based
on mass spectrometry, 1D, and 2D nuclear magnetic resonance spectral data, as well as comparison with reported data.
The interaction of the compound with the protein, which involves to HCV activity, was determined by docking analysis.
Three known methoxyflavone compounds identified as 5,4'-dihydroxy-7-prenyloxy-3,8,5’-trimethoxyflavone (1); 5,3'-
dihydroxy-3,7,8,4'-tetramethoxyflavone (2); and 5-hydroxy-3,7,8,3',4'-pentamethoxyflavone (3) were isolated from the
ethanolic extract of M. latifolia leaves. Anti-HCV activities revealed that compound (1) strongly inhibited HCV J6/JFH1
with a 50% inhibitory concentration (IC50) value of 6.7±0.4 µg/mL and 50% cytotoxic concentration (CC50) of 19.3
µg/mL. The docking analysis revealed an interaction with the 4GAG, a protein that involves in the entry step of HCV,
and the 4EAW protein which plays an important role during HCV replication.
AntiHCV Infectious disease Melicope latifolia medicine hepatitis health
Birincil Dil | İngilizce |
---|---|
Konular | Eczacılık ve İlaç Bilimleri (Diğer) |
Bölüm | Articles |
Yazarlar | |
Yayımlanma Tarihi | 28 Haziran 2025 |
Yayımlandığı Sayı | Yıl 2023 Cilt: 27 Sayı: 3 |